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Abstract: The increasing of intracellular calcium concentration is a fundamental process for mediating
osteoclastogenesis, which is involved in osteoclastic bone resorption. Cytosolic calcium binds
to calmodulin and subsequently activates calcineurin, leading to NFATc1 activation, a master
transcription factor required for osteoclast differentiation. Targeting the various activation processes
in osteoclastogenesis provides various therapeutic strategies for bone loss. Diverse compounds
that modulate calcium signaling have been applied to regulate osteoclast differentiation and,
subsequently, attenuate bone loss. Thus, in this review, we summarized the modulation of the
NFATc1 pathway through various compounds that regulate calcium signaling and the calcium influx
machinery. Furthermore, we addressed the involvement of transient receptor potential channels
in osteoclastogenesis.
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1. Osteoclastogenesis in Bone Remodeling
Bone remodeling is balanced by the coordinated activities of osteoclastic resorption and
osteoblastic formation [1]. Imbalanced bone remodeling leads to bone diseases including osteoporosis,
periodontitis and rheumatoid arthritis, which are characterized by enhanced osteoclast activity. In other
words, an excessive increase in osteoclast differentiation and bone resorption gives rise to various
bone-resorptive diseases [2]. Osteoclasts are the cells responsible for bone resorption. These large
multinucleated cells originate from the monocyte/macrophage hematopoietic lineage [3,4]. Osteoclast
differentiation depends on two essential cytokines, receptor activator of nuclear factor-κB (NF-κB)
ligand (RANKL) and macrophage colony-stimulating factor (M-CSF) [5–7]. M-CSF is involved in
the proliferation and survival of osteoclast precursors and RANKL induce osteoclast differentiation
through binding to its receptor RANK and subsequent activation of nuclear factor of activated T
cells (NFATc1), a master transcription factor required for osteoclast differentiation [8]. Osteoclasts are
formed by the fusion of osteoclast precursor cells. Cellular fusion is an essential element in osteoclast
development that results in the formation of multinucleated giant cells responsible for bone resorption
activity. This process is called osteoclastogenesis. To resorb bone, osteoclasts attach to the bone surface,
form a “ruffled border” and dissolve bone mineral by massive secretion of acidic elements [3].
2. The Role of Calcium (Ca2+) Signaling in Osteoclastogenesis
Ca2+ signaling in osteoclasts is important for multiple cellular functions, including proliferation,
differentiation, gene transcription and bone resorption [9]. Ca2+ is released from intracellular stores,
Int. J. Mol. Sci. 2020, 21, 3646; doi:10.3390/ijms21103646 www.mdpi.com/journal/ijms
Int. J. Mol. Sci. 2020, 21, 3646 2 of 21
or enters the cell via plasma membrane ion channels [10]. RANKL-mediated signaling in osteoclasts
is the initial step of bone resorption initiation. RANK-bound RANKL induces activation of the
tumor necrosis factor (TNF) receptor-associated factor 6 (TRAF6) [11], subsequently involved in
the activation of mitogen-activated protein kinases (MAPKs), nuclear factor-κB (NF-κB), and a
component of activator protein-1 (AP-1) [8,12,13]. Activated NF-κB induces NFATc1 transcription
to differentiate osteoclasts [6,14]. RANKL also stimulates phospholipase Cγ (PLCγ) during the
early stages of osteoclastogenesis. Activated PLCγ produces inositol 1, 4, 5-triphosphate (IP3) in
the cytosol. Son et al. [15] reported that RANKL-mediated activation of PLC induces an increase of
cytosolic IP3 levels, which increases intracellular Ca2+ concentration ([Ca2+]i) through inducing its
release from the endoplasmic reticulum (ER). Ca2+ influx through store-operated Ca2+ entry (SOCE)
and transient receptor potential (TRP) channels causes RANKL-induced [Ca2+]i oscillations during
osteoclastogenesis [16–19]. TRP channels are involved in not only extracellular but also intracellular
Ca2+ balance in osteoclasts [20]. Ca2+ release and reuptake into the ER stores is also necessary
for [Ca2+]i oscillations. Sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) transports Ca2+ from
the cytosol into the ER, and SERCA activity is also essential for [Ca2+]i oscillations. Disruption of
SERCA2 expression impairs RANKL-induced [Ca2+]i oscillations [21]. Furthermore, RANKL induces
a reactive oxygen species (ROS) pathway and causes long lasting [Ca2+]i oscillations [22]. Cytosolic
Ca2+ binds to calmodulin (CaM), which results in the activation of CaM-dependent enzymes such as
the phosphatase calcineurin [23]. Activated calcineurin dephosphorylates serine residues in NFATc1,
resulting in translocation of NFATc1 into the nucleus [24,25]. A recent study using Homer2 and
Homer3 (Homer2/3) double-knockout (DKO) mice showed that Homer proteins regulate NFATc1
function through interaction with calcineurin to regulate RANKL-induced osteoclastogenesis [26].
Thus, increased [Ca2+]i is a fundamental process mediating osteoclastogenesis (Figure 1). In this review,
we focused on modulation of Ca2+ signaling through Ca2+ influx via TRP channels and highlighted
the diverse compounds, involved in the Ca2+ -mediated signaling pathway, in osteoclastogenesis.
3. Transient Receptor Potential (TRP) Channels in Osteoclast
Cytosolic Ca2+ modulation is crucial in osteoclastogenesis. TRP channels are widely expressed in
several mammalian tissues and involved in diverse physiological processes such as differentiation,
proliferation, and apoptosis [27,28]. Several studies have focused on TRP channels as Ca2+-influx
channels in RANKL-induced osteoclastogenesis. Generally, TRP channels are non-selective cation
channels and are divided into six subfamilies: canonical (TRPCs), vanilloid (TRPVs), melastatin
(TRPMs), mucolipin (TRPMLs), polycystins (TRPPs), and ankyrin (TRPA) [29]. Among the TRP
channels, TRPV2 [30], TRPV4 [31], and TRPV5 [32] contribute to intracellular Ca2+ signaling in osteoclast
differentiation. TRPC1 also regulates osteoclast differentiation through SOCE [33]. This section
discusses the roles of TRPC, TRPV, and TRPML channels in osteoclastogenesis.
3.1. TRPC
Mildly enhanced bone mass was observed in TRPC1 null mice and its effect was revealed only
in mice lacking inhibitor of MyoD family isoform a (I-mfa) [33]. TRPC1 binds I-mfa [34]. Trpc1
and I-mfa functionally interact to regulate the early differentiation stage of the osteoclast through
antagonistic regulation of SOCE. Although there are limited studies on TRPC, the modulation of the
Ca2+ release-activated Ca2+ current (ICRAC) by TRPC1, and I-mfa is crucial for NFATc1 activation and
subsequent osteoclast differentiation [33].
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Figure 1. Schematic illustration of Ca2+ signaling in osteoclastogenesis. (A) RANK on the surface of 
osteoclast progenitor activates signaling by RANKL on the surface of osteoblasts/stromal cell to 
promote osteoclastogenesis. (B) Osteoclast precursor stage. In the early stages of osteoclastogenesis, 
RANK-bound RANKL induces activation of TRAF6 and stimulates PLCγ. PLCγ produces IP3, which 
evokes Ca2+ release from the ER. In addition, RANK-bound RANKL induces lysosomal Ca2+ release 
through TRPML1 and generates Ca2+ oscillation. SOCE, VGCC and TRPV2 are also involved in Ca2+ 
oscillation. The Ca2+ oscillations induce Ca2+-calcineurin-NFATc1 signaling. In the late stages of 
osteoclastogenesis, the Ca2+ oscillation is sustained by TRPV4-mediated Ca2+ influx. In the nucleus, 
NFATc1 induces the expression of various osteoclast-specific genes. (C) In mature osteoclasts, 
Figure 1. Schematic illustration of Ca2+ signaling in osteoclastogenesis. (A) RANK on the surface
of osteoclast progenitor activates sign li g by RANKL on the surface f o teobl sts/stromal cell to
promote osteoclastogenesis. (B) Osteoclast prec rsor stage. In the early stages of steoclastogenesis,
RANK-bound RANKL induces activation of TRAF6 and stimulates PLCγ. PLCγ produces IP3, which
evokes Ca2+ release from the ER. In addition, RANK-bound RANKL induces lysosomal Ca2+ release
through TRPML1 and generates Ca2+ oscillation. SOCE, VGCC and TRPV2 are also inv lved in Ca2+
oscillation. The Ca2+ oscillations induce Ca2+-calcineurin-NFATc1 signaling. In the late stages of
osteoclastogenesis, the Ca2+ oscillation is sustained by TRPV4-mediated Ca2+ influx. In the nucleus,
NFATc1 induces the expression of various osteoclast-specific genes. (C) In mature osteoclasts, TRPV4
and TRPV5 in the basolateral membrane are necessary for the regulation of osteoclastic bone resorption.
TRPV5 is predominantly located on the ruffled border of resorbing osteoclasts. Abbreviations: RANKL,
receptor activator of nuclear factor-κB (NF-κB) ligand; RANK, receptor activator of nuclear factor-κB
(NF-κB); NFATc1, nuclear factor of activated T cells cytoplasmic 1; TRAF6, tumor necrosis factor (TNF)
receptor-associated factor 6; PLCγ, phospholipase Cγ; IP3, inositol 1,4,5-triphosphate; ER, endoplasmic
reticulum; Ca2+, calcium; [Ca2+]i, intracellular Ca2+ concentration; SOCE, store-operated Ca2+ entry;
VGCC, voltage-gated Ca2+ channel; TRPV2, transient receptor potential vanilloid 2; TRPV4, transient
receptor potential vanilloid 4; TRPV5, transient receptor potential vanilloid 5; TRPML1, transient
receptor potential mucolipin 1.
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3.2. TRPV
TRPV family members act as sensory channels for receptor-operated Ca2+ influx and are critically
involved in the regulating of osteoclast differentiation [20]. The TRPV family consists of six members,
TRPV1–TRPV6, composed of six transmembrane domains that form a cation-permeable pore [35–37].
Among the TRPV family members, TRPV1 is a non-selective cation channel activated by various
stimuli such as heat, noxious stimuli, low pH, and numerous chemicals [38]. The physiological role of
TRPV1 in bone biology was addressed one decade ago. TRPV1 is expressed in osteoclasts and promotes
their differentiation [39]. Human osteoclast expresses functional TRPV1, as well as the cannabinoid
receptors type 1 and 2 (CB1/CB2). The involvement of both receptors is controversial. Expression
levels of TRPV1 are enhanced in osteoclasts derived from osteoporotic subjects, whereas CB2 are
reduced [40]. More recently, TRPV1 desensitization and/or CB2 stimulation were found beneficial for
reducing osteoclast over-activity [41,42]. There are several reports showing that application of the
TRPV1 agonist capsaicin suppresses LPS-induced prostaglandin E2 (PGE2) production in osteoblasts
and suppressed LPS-induced osteoclast formation [39,43]. On the other hand, the TRPV1 antagonist
capsazepine inhibits bone formation and bone resorption activity of osteoclasts in OVX mice [44].
[6]-Gingerol, a major constituent of ginger, augments osteoclast function via TRPV1 and induces bone
loss in adult ovary-intact mice [45]. Zoledronic acid is nitrogen containing bisphosphonate that inhibit
bone resorption. Effects of the Zoledronic acid were antagonized by capsazepine supporting the
involvement of TRPV1 channel in osteoblastogenesis and mineralization, but this mechanism is not
effective in osteoclasts lacking the TRPV1 [46]. Sirtuin 1 (SIRT1), also known as nicotinamide adenine
dinucleotide (NAD+)-dependent lysine deacetylase, directly inhibits the osteoclast differentiation by
inhibiting ROS generation and TNF-α-mediated TRPV1 channel activation [47]. In addition, TRPV1,
as a pain receptor, is expressed in peripheral sensory nerves [48,49]. A pathological role of TRPV1 has
been revealed in both osteoporosis and osteoarthritis [41,50].
TRPV2 is closely related to TRPV1 [38,51]. TRPV2 is expressed in RANKL-treated RAW264.7
cells and TRPV2-mediated spontaneous [Ca2+]i oscillations activate NFATc1 and promote osteoclast
differentiation [30]. More recently, TRPV2 was found to regulate RANKL-dependent osteoclastic
differentiation through the Ca2+-calcineurin-NFATc1 signaling pathway in multiple myeloma (MM)
patients [52].
TRPV4 also plays an essential role in osteoclast differentiation [31]. It is known as a mechano-
and osmo-sensor [53,54], and localizes to the basolateral membranes of mature osteoclasts [31].
TRPV4-mediated Ca2+ influx and intracellular Ca2+ signaling activate NFATc1 and induce osteoclast
differentiation and resorption activity [31,55]. A protein–protein interaction between TRPV4 and
myosin IIa regulates Ca2+/CaM signaling, which supports the migration and fusion of osteoclast
precursors [55]. In addition, the TRPV4-specific antagonist, RN1734, inhibits osteoclast formation,
whereas the TRPV4-specific agonist 4-α-PDD enhances osteoclast formation under mild acidic
conditions [56,57]. Stromal interaction molecule 1 (STIM1)-mediated SOCE is involved in fluid
shear stress (FSS)-induced [Ca2+]i oscillations at the early differentiation stage of osteoclasts, whereas
TRPV4 is highly associated with the Ca2+ response at the late stage of differentiation under FSS
simulation [58]. TRPV4 knockdown significantly suppresses osteoclast differentiation and osteoporosis
by inhibiting the Ca2+-calcineurin-NFATc1 pathway [59].
TRPV5, a highly selective Ca2+ channel, is activated by low [Ca2+]i [60]. It is predominantly located
on the ruffled borders of the membranes of resorbing osteoclasts [32]. TRPV5 knockout mice showed
increased osteoclast numbers and reduced trabecular and cortical bone thickness [61]. In contrast,
TRPV5 knockout mice had impaired osteoclastic function in vivo [32]. Although controversial, these
findings suggest that TRPV5 plays an important role in osteoclastic function, again demonstrating
the significance of Ca2+ influx in mature osteoclasts. In addition, small interfering RNA (siRNA)
knockdown of TRPV5 completely inhibits RANKL-induced Ca2+ influx at the late differentiation stage
of osteoclasts in vitro and enhances bone resorption activity in human osteoclasts [20,62]. The lack of
estrogen leads to osteoporosis. Estrogen inhibits osteoclast differentiation and bone resorption activity
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by increasing TRPV5 expression in postmenopausal osteoporosis [63]. Song et al. also demonstrated
that estrogen increases TRPV5 expression through the interaction of the estrogen receptor α (ERα) in
RAW 264.7 cells. Furthermore, NF-κB binds to the putative site on the trpv5 promoter, and TRPV5 is
regulated by NF-κB [64]. Thus, TRPV5 contributes to the processes of estrogen-mediated osteoclast
formation, bone resorption activity, and osteoclast apoptosis. A recent study showed that vitamin D
(1,25(OH)2D3) inhibits TRPV5 expression at the early stage of osteoclastogenesis by suppressing
osteoclast differentiation [65].
3.3. TRPML
The TRPML family has three members: TRPML1, TRPML2, and TRPML3. Among these, TRPML1
is a non-selective cation channel that permeates Ca2+ [66]. TRPML1 is a Ca2+-permeable channel in
lysosomes and plays vital roles in lysosomal trafficking and functions [67]. Erkhembaatar et al. [68]
showed that deleting TRPML1 inhibits RANKL-induced [Ca2+]i oscillations, which reduces
osteoclastogenesis and bone remodeling.
4. Diverse Compounds Modulating Ca2+ Signaling in Osteoclastogenesis
Osteoclasts are responsible for bone resorption and are therefore considered targets of
anti-osteoporosis therapies. Novel treatment strategies aimed at preventing excessive bone resorption
have been studied [69]. The study of antiresorptive agents derived from diverse compounds has
become a recent topic of interest. The aim of this section is to summarize the current knowledge on
diverse compounds that regulate osteoclast differentiation by modulating Ca2+ signaling. Thus, in this
section, we mentioned by listing diverse compounds depending on their mode of action. Table 1 and
Figure 2 summarize diverse compounds that regulate Ca2+ signaling in osteoclastogenesis.
4.1. Ca2+-Calcineurin-NFATc1 (CCN) Pathway
4.1.1. KMUP-1
KMUP-1 (7-[2-[4-(2-chlorophenyl)piperazinyl]ethyl]-1,3-dimethylxanthine), a chemical synthetic
xanthine-based derivative, effectively suppresses RANKL-induced osteoclast differentiation in vitro,
and also attenuated ovariectomized (OVX)-induced osteoclast differentiation and prevented bone
resorption in vivo [18]. Especially KMUP-1 inhibits RANKL-induced [Ca2+]i oscillations, and
subsequently, inhibits calcineurin-NFATc1 signaling [70].
4.1.2. Zinc
It has been shown that zinc, an important trace element, inhibits osteoclast differentiation by
suppressing the Ca2+-calcineurin-NFATc1 signaling pathway in vitro and in vivo [19]. Specifically,
zinc inhibits calcineurin activity but not expression and RANKL-induced [Ca2+]i oscillations, without
decreasing PLCγ phosphorylation. In addition, it was proposed that zinc inhibits calcineurin in the
early stage of osteoclast differentiation and [Ca2+]i oscillations in the middle or late stage of osteoclast
differentiation [71].
4.1.3. Praeruptorin A
Praeruptorin A is isolated from the dried root of Peucedanum praeruptorum Dunn. It also
has anti-osteoclastogenic activity by inhibiting [Ca2+]i oscillations without decreasing PLCγ
phosphorylation [72].
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Table 1. Diverse compounds that regulate Ca2+ signaling in osteoclastogenesis.
Compound Mechanism of Inhibition of RIO (1) Species
Administered Dose
Ref
In Vitro In Vivo
Mode of action: Ca2+-Calcineurin-NFATc1(CCN (2)) signaling
KMUP-1 CCN signaling independently of PLCγ RAW264.7 cell,BALB/c mice 1–10 µM 1, 5, 10 mg/kg [70]
Zinc CCN signaling independently of PLCγ RAW264.7 cell,BMMs (C57BL/6 mice) 10–100 µM N/A
(4) [71]
Praeruptorin A Inhibition of PLCγ-independent [Ca2+]i oscillations BMMs (ICR mice) 10 µM N/A [72]




5–10 µM 5 mg/kg [73]




7.5–10 µM 7.5 mg/kg [74]
Asiaticoside Suppression of NF-κB and CCN signaling RAW264.7 cell,BMMs (C57BL/6 mice) 2.5–20 µM N/A [75]
Mode of action: PLCγ- Ca2+-NFATc1(PCN (3)) signaling
OAA PCN signaling BMMs (ICR mice),ICR mice 20 µM 10 mg/kg [76]
HAR Syk-Btk-PLCγ- Ca2+ Signaling
BMMs (ICR mice),





3.125–12.5 µM 5, 30 mg/kg [78]
MG Akt and Btk-PLCγ- Ca2+ Signaling
BMMs (ICR mice),
ICR mice 1–10 µM 10 mg/kg [79]
Berberine * Inhibition of LPS-induced osteoclastogenesis throughTRAF6 and PCN signaling RAW264.7 cell 5–20 µM N/A [80]
TN Suppression of Btk-PLCγ cascade, NF-κB, MAPKs andCCN signaling BMMs (C57BL/6 mice) 1.25–5 µM N/A [81]
Physalin D Suppression of PLCγ-CaMK-CREB pathway BMMs (C57BL/6 mice),C57BL/6 mice 5 µM 10, 100 mg/kg [82]
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Table 1. Cont.
Compound Mechanism of Inhibition of RIO (1) Species
Administered Dose
Ref
In Vitro In Vivo
Mode of action: Negative regulation of Ca2+ signaling
GH
Abrogation of RANKL-induced [Ca2+]i oscillations by
inactivating VGCCs independently of Ca2+ release from
intracellular Ca2+ stores
BMMs (C57BL/6 mice) 5–50 µg/mL N/A [83]
PO Suppression of RANKL-induced [Ca
2+]i oscillations by
inhibiting Ca2+ release from intracellular Ca2+ stores
murine BMMs 50 µg/mL N/A [84]
MTX Decrease of RANKL-induced Ca2+ influx BMMs (C57BL/6 mice) 1, 5 µM N/A [85]




C57BL/6 mice 0.1, 1 µM 0.5, 5 mg/kg [86]
SIN * Inhibition of LPS-induced osteoclastogenesis bydecreasing expression of NF-κB, AP-1 and Ca2+-NFATc1
RAW264.7 cell,
C57BL/6 mice 0.25–1 mM
25, 50, 100
mg/kg [87]
Dried plum fractions Suppression of MAPKs and Ca
2+ signaling, resulting in
inhibition of NFATc1
RAW264.7 cell,
BMMs (C57BL/6 mice) 1, 10 µg/mL N/A [88]
KN93 Decreasing of [Ca2+]i RAW264.7 cell 10 µM N/A [89]




5–10 µM 10 mg/kg [90]
Methylglyoxal Suppression of [Ca
2+]i, mitochondrial biogenesis,
mitochondrial membrane potential, and glyoxalase I
RAW264.7 cell 10–200 µM N/A [91]
APO Decreasing of [Ca2+]i BMMs (C57BL/6 mice) 1 µM N/A [92]
LrB Suppression of [Ca





5–10 µM 4 mg/kg [93]
CRT
Suppression of RANKL-induced [Ca2+]i oscillations and





0.5–500 ng/ml 0.2 mg/kg [94]
6-Shogaol Suppression of [Ca
2+]i oscillations, ROS production, and
NFATc1 activity
BMMs (C57BL/6 mice),
C57BL/6 mice 2.5–10 µM 10 mg/kg [95]
Mode of action: Increasing [Ca2+]i oscillations
Aβ
* Enhancement of osteoclast activation by activating NF-κB,
ERK and increasing [Ca2+]i oscillations, resulting in
upregulation of NFAT-c1
BMMs (C57BL/6 mice) 1–10 µM N/A [96]
* Another mechanism besides RIO, Abbreviations: (1) RIO, RANKL-induced osteoclastogenesis; (2) CCN, Ca2+-Calcineurin-NFATc1; (3) PCN, PLCγ- Ca2+-NFATc1; (4) N/A, not applicable;
The other abbreviations are listed in the last paragraph.
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osteoclastogenesis. KMUP-1 (7-[2-[4-(2-chlorophenyl)piperazinyl]ethyl]-1,3-dimethylxanthine), Zinc, 
Praeruptorin A, Cyanidin Chloride, Lumichrome and Asiaticoside inhibit osteoclastogenesis via 
inhibiting Ca2+-Calcineurin-NFATc1 signaling independent of PLCγ. Methotrexate (MTX), 
Xanthotoxin (XAT), Sinomenine (SIN), Dried plum fractions, KN93, Cajaninstilbene acid (CSA), 
Methylglyoxal, Apocynin (APO), Loureirin B (LrB), Calreticulin (CRT) and 6-Shogaol inhibit 
osteoclastogenesis via decreasing [Ca2+]i. On the contrary, Amyloid beta peptide (Aβ) enhances 
osteoclastic bone resorption by increasing [Ca2+]i oscillations, resulting in upregulation of NFATc1. 
Portulaca oleracea (PO) inhibits osteoclastogenesis by inhibiting Ca2+ release from intracellular Ca2+ 
stores. Oleanolic acid acetate (OAA), Artesunate, Berberine and Physalin D inhibit osteoclastogenesis 
via inhibiting PLCγ-Ca2+-NFATc1 signaling. Harpagoside (HAR) inhibits osteoclastogenesis via 
inhibiting Syk-Btk-PLCγ-Ca2+ Signaling. Methyl gallate (MG) and Tatarinan N (TN) inhibit 
osteoclastogenesis by suppression of Btk-PLCγ cascade. Glechoma hederacea (GH) inhibits 
osteoclastogenesis by inactivating VGCCs independent of Ca2+ release from intracellular Ca2+ stores. 
Abbreviations: RANKL, receptor activator of nuclear factor-κB (NF-κB) ligand; RANK, receptor 
activator of nuclear factor-κB (NF-κB); NFATc1, nuclear factor of activated T cells cytoplasmic 1; 
TRAF6, tumor necrosis factor (TNF) receptor-associated factor 6; MAPK, mitogen-activated protein 
kinases; AP-1, activator protein-1; Btk, Bruton’s tyrosine kinase; Syk, spleen tyrosine kinase; PLCγ, 
phospholipase Cγ; IP3R, inositol 1,4,5-triphosphate receptor; ER, endoplasmic reticulum; Ca2+, 
calcium; [Ca2+]i, intracellular Ca2+ concentration; SOCE, store-operated Ca2+ entry; VGCC, 
voltage-gated Ca2+ channel; TRP channels, transient receptor potential cation channels; CaMKs, 
Figure 2. The schematic illustration summarized diverse compounds that regulate Ca2+ signaling
in osteoclastogenesis. KMUP-1 (7-[2-[4-(2-chlorophenyl)piperazinyl]ethyl]-1,3-dimethylxanthine),
Zinc, Praeruptorin A, Cyanidin Chloride, Lumichrome and Asiaticoside inhibit osteoclastogenesis via
inhibiting Ca2+-Calcineurin-NFATc1 signaling independent of PLCγ. Methotrexate (MTX), Xanthotoxin
(XAT), Sinomenine (SIN), Dried plum fractions, KN93, Cajaninstilbene acid (CSA), Methylglyoxal,
Apocynin (APO), Loureirin B (LrB), Calreticulin (CRT) and 6-Shogaol inhibit osteoclastogenesis
via decreasing [Ca2+]i. On the contrary, Amyloid beta peptide (Aβ) enhances osteoclastic bone
resorption by increasing [Ca2+]i oscillations, resulting in upregulation of NFATc1. Portulaca
oleracea (PO) inhibits osteoclastogenesis by inhibiting Ca2+ release from intracellular Ca2+ stores.
Oleanolic acid acetate (OAA), Artesunate, Berberine and Physalin D inhibit osteoclastogenesis via
inhibiting PLCγ-Ca2+-NFATc1 signaling. Harpagoside (HAR) inhibits osteoclastogenesis via inhibiting
Syk-Btk-PLCγ-Ca2+ Signaling. Methyl gallate (MG) and Tatarinan N (TN) inhibit osteoclastogenesis by
suppression of Btk-PLCγ cascade. Glechoma hederacea (GH) inhibits osteoclastogenesis by inactivating
VGCCs independent of Ca2+ release from intracellular Ca2+ stores. Abbreviations: RANKL, receptor
activator of nuclear factor-κB (NF-κB) ligand; RANK, receptor activator of nuclear factor-κB (NF-κB);
NFATc1, nuclear factor of activated T cells cytoplasmic 1; TRAF6, tumor necrosis factor (TNF)
receptor-associated factor 6; MAPK, mitogen-activated protein kinases; AP-1, activator protein-1;
Btk, Bruton’s tyrosine kinase; Syk, spleen tyrosine kinase; PLCγ, phospholipase Cγ; IP3R, inositol
1,4,5-triphosphate receptor; ER, endoplasmic reticulum; Ca2+, calcium; [Ca2+]i, intracellular Ca2+
concentration; SOCE, store-operated Ca2+ entry; VGCC, voltage-gated Ca2+ channel; TRP channels,
transient receptor potential cation channels; CaMKs, Ca2+/calmodulin dependent protein kinases;
CREB, cAMP-responsive element-binding protein; CaM, calmodulin.
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4.1.4. Cyanidin
Cyanidin, a particular type of anthocyanidins, is the sugar-free counterpart of anthocyanins.
Anthocyanins are reddish pigments widely spread in colored fruits and vegetables [97,98]. Cyanidin
chloride inhibits RANKL-induced osteoclast formation and osteoclast resorptive activity in vitro
and protects against OVX-induced bone loss in vivo. Furthermore, cyanidin chloride impairs
RANKL-induced [Ca2+]i oscillations, which leads to the suppression of the activation of NFATc1 in
cultured primary bone marrow-derived macrophages (BMMs) [73]
4.1.5. Lumichrome
Lumichrome is a natural metabolite of riboflavin, a member of the B family of vitamins, and
has been shown to have a beneficial effect on bone formation [99,100]. Chuan et al. [74] found
that lumichrome inhibits RANKL-induced [Ca2+]i oscillations in BMMs. Furthermore, lumichrome
suppresses NFATc1, NF-κB, and MAPK signaling activation and decreases bone loss in OVX-mice by
inhibiting osteoclastogenesis.
4.1.6. Asiaticoside
Asiaticoside, a natural compound, is extracted from Centella asiatica and is a member of the
triterpenoid family [101]. It significantly inhibits RANKL-induced [Ca2+]i oscillations and NFATc1
expression in BMMs. Therefore, Asiaticoside suppresses the differentiation and function of the osteoclast
via inhibiting the NF-κB and NFATc1 pathways [75].
4.2. PLCγ-Ca2+-NFATc1 (PCN) Pathway
4.2.1. Oleanolic Acid Acetate
Oleanolic acid acetate (OAA) is a compound isolated from Vigna angularis (azuki bean).
Kim et al. [76] have reported that OAA negatively regulates osteoclast differentiation by RANKL-induced
PLCγ2 and [Ca2+]i oscillations, which leads to NFATc1 activation. In vitro, OAA inhibits RANKL-induced
osteoclast differentiation through PLCγ2-Ca2+-NFATc1 signaling. OAA administration also suppresses
lipopolysaccharide (LPS)-induced bone loss in vivo.
4.2.2. Harpagoside
Harpagoside (HAR), an iridoid glycoside isolated from Harpagophytum procumbens (devil’s claw),
inhibits [Ca2+]i oscillations via inactivation of several kinases such as Bruton’s tyrosine kinase (Btk),
spleen tyrosine kinase (Syk), and PLCγ2, which leads to the suppression of RANKL-induced osteoclast
differentiation [77]. HAR also restored bone density in an LPS-induced, but not in an OVX-induced
bone loss mouse model in vivo [77].
4.2.3. Artesunate
Artesunate is one of the effective clinical treatments for falciparum malaria [102]. It suppresses
RANKL-induced Ca2+ influx and calcineurin expression. Furthermore, phosphorylation of PLCγ1
is decreased by artesunate treatment in RANKL-stimulated RAW264.7 cells. Therefore, artesunate
suppresses RANKL-induced osteoclast differentiation and function by inhibiting the PLCγ1-Ca2+-
calcineurin-NFATc1 pathway [78].
4.2.4. Methyl Gallate
Methyl gallate (MG) is a polyphenolic compound that is known to have antioxidant [103],
antitumor [104], anti-inflammatory [105], and antimicrobial activities [106]. MG is a dominant inhibitor
of sodium and potassium ion channels in skeletal muscle cells [107]. Baek et al. [79] showed that
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MG attenuates RANKL-induced osteoclast differentiation by inhibiting both Akt (Protein kinase B)
phosphorylation and intracellular Ca2+ influx mediated by Btk and PLCγ2.
4.2.5. Berberine Hydrochloride
Berberine hydrochloride, an isoquinoline alkaloid, is found in many plants of the Berberidaceae
families [108]. It inhibits the activation of PLCγ1, and thereby, inhibits Ca2+ influx, which reduces
intracellular Ca2+ concentration, and subsequently, inhibits osteoclast differentiation and bone
destruction through suppression of the TRAF6-Ca2+-calcineurin-NFATc1 signaling pathway in
LPS-stimulated RAW264.7 cells [80].
4.2.6. Tatarinan N
Tatarinan N (TN), a lignin-like component, is extracted from Acorus tatarinowii Schott [109].
It attenuates RANKL-induced osteoclast differentiation via reducing NFATc1 and c-Fos expression
as well as inhibiting the ERK1/2 or p38 signaling pathway. Besides, TN significantly reduces the
elevation of intracellular Ca2+ concentration induced by RANKL and attenuates RANKL-induced
phosphorylation of Btk and PLCγ2 in a dose-dependent manner in BMMs [81].
4.2.7. Physalin D
Physalin D is isolated from Physalis alkekengi L., known as “winter cherry”, and grows in western
Asia and Europe [110]. Physalin D has been shown to have anti-inflammatory, antimalarial, and
antinociceptive effects [110–112]. Physalin D attenuates RANKL-induced [Ca2+]i oscillations by
inhibiting phosphorylation of PLCγ2 and blocks the downstream activation of Ca2+/calmodulin-
dependent protein kinase (CaMK) type IV and cAMP-responsive element-binding protein (CREB) in
BMMs. Moreover, physalin D protects RANKL-induced bone loss in vivo [82].
4.3. Negative Regulation on Ca2+ Signaling
4.3.1. Glechoma Hederacea
Glechoma hederacea (GH), known as ‘ground ivy’ or ‘creeping Charlie’, is a perennial hairy herb of
the mint family Lamiaceae. Hwang et al. [83] have shown that GH induces a transient and large increase
in [Ca2+]i, through the involvement of Ca2+ influx via voltage-gated Ca2+ channels (VGCCs), resulting
in the abrogation of RANKL-induced [Ca2+]i oscillations and the inhibition of NFATc1 expression
in BMMs. However, GH-induced intracellular [Ca2+]i elevation was independent of Ca2+ release
from intracellular Ca2+ stores in BMMs. Taken together, these findings suggest that GH abrogates
RANKL-induced [Ca2+]i oscillations, inhibits NFATc1 expression, and reduces osteoclast differentiation
by inactivating VGCCs.
4.3.2. Portulaca Oleracea
Portulaca oleracea (PO), also known as verdolaga, red root, or pursley, has been widely used as
traditional medicine. PO ethanol extract (POEE) has dual and contrary effects on RANKL-induced
osteoclast differentiation. The POEE inhibits RANKL-induced [Ca2+]i oscillations and NFATc1
activation, while it enhances RANKL-induced osteoclast differentiation by reducing RANKL-mediated
cytotoxicity. Erkhembaatar et al. [84] proposed that RANKL-mediated cytotoxicity due to Ca2+ release
from intracellular Ca2+ stores is attenuated by POEE, which leads to enhanced RANKL-induced
osteoclast differentiation.
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4.3.3. Methotrexate
Methotrexate (MTX) is used to treat sarcoma, leukemia, and auto-inflammatory diseases such as
rheumatoid arthritis [113,114]. MTX inhibits osteoclast differentiation by inhibiting RANKL-induced
Ca2+ influx in osteoclast progenitor cells [85].
4.3.4. Xanthotoxin
Xanthotoxin (XAT) is isolated from the seeds of a plant of the carrot family Ammi majus [115].
XAT has been shown to have antitumor activity and antioxidant activity [116,117]. Interestingly, XAT
affects the intracellular Ca2+ levels in melanocytes, resulting in reorganization of actin stress fiber
cytoskeleton [118]. Dou et al. [86] showed that XAT suppresses RANKL-induced [Ca2+]i oscillations
and the activation of downstream targets of Ca2+-CaMKK (Calmodulin-dependent protein kinase
kinase)/Pyk2 (Proline-rich tyrosine kinase 2) signaling during osteoclast differentiation, resulting in the
inhibition of NFATc1 and c-FOS in BMMs. In addition, an in vivo study showed that XAT treatment
prevents bone loss and increases new bone formation in OVX-mice.
4.3.5. Sinomenine
Sinomenine (SIN) is an alkaloid found in the roots and stems of Sinomenium acutum. SIN has
been used for the treatment of rheumatoid arthritis (RA) in China [119]. SIN dramatically reduces
LPS-induced upregulation of intracellular Ca2+ in matured RAW264.7 cells. In addition, SIN decreases
expression of osteoclast-specific genes and tumor necrosis factor-α (TNF-α) production, and inhibits
LPS-induced osteolysis and osteoclast differentiation in vitro and in vivo [87].
4.3.6. Dried Plum Fractions
In preclinical trials, bone resorption is decreased by dietary supplementation with dried plum in
ovariectomized rat and mouse models [120,121]. Graef et al. [88] showed that polyphenolic compounds
in dried plums suppress intracellular Ca2+ signaling and MAPK signaling, resulting in the inhibition
of NFATc1 expression, which reduces osteoclast differentiation in BMMs.
4.3.7. KN93
KN93 is an inhibitor of multifunctional Ca2+/CaMKs [122]. It inhibits the formation and activation
of the osteoclast. KN93 also downregulates the expression of NFATc1 and AP-1 protein family members
in RANKL-stimulated RAW 264.7 cells. Furthermore, KN93 significantly decreases intracellular Ca2+
concentration in differentiated osteoclasts [89].
4.3.8. Cajaninstilbene Acid
Cajaninstilbene acid (CSA) is a bioactive compound derived from pigeon pea leaves [123]. It suppresses
osteoclast differentiation and bone resorption via inhibiting RANKL-induced ROS activity and [Ca2+]i
oscillations in RAW264.7 cells and BMMs. CSA also protects the bone loss of OVX- induced C57BL/6
mice [90].
4.3.9. Methylglyoxal
Methylglyoxal is derived from organic compounds and is a precursor of advanced glycation end
products. Its formation involves several metabolic pathways [124]. The formation of Methylglyoxal
is increased in diabetic patients [125]. Diabetes can give rise to a state of low bone turnover
osteoporosis [126]. The Methylglyoxal decreases [Ca2+]I, mitochondrial biogenesis, mitochondrial
membrane potential, and glyoxalase I, resulting in the inhibition of RANKL-induced osteoclast
differentiation and bone resorbing activity in RAW264.7 cells [91].
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4.3.10. Apocynin
The catechol apocynin (APO) is used as a NADPH oxidase (NOX) inhibitor [127]. Soares et al. [92]
evaluated the effects of APO on osteoclast differentiation. APO reduces [Ca2+]i by blocking Ca2+
channels except two pore segment channel 2 (TPC2) and inositol 1,4,5-triphosphate receptor type 1
(IP3R1). TPC2 is a Ca2+-permeable channel expressed in lysosomes, and IP3R1 is a Ca2+ channel that
mediates Ca2+ release from the ER, following IP3 stimulation. APO inhibits osteoclast differentiation
by decreasing [Ca2+]i.
4.3.11. Loureirin B
Loureirin B (LrB) is an active component isolated from Sanguis draxonis, which is a Chinese
traditional herb also known as Dragon’s Blood [128]. Yuhao et al. [93] investigated the effects of LrB on
RANKL-induced osteoclast activity in vitro and in an OVX-induced osteoporosis mouse model in vivo.
LrB attenuates RANKL-induced [Ca2+]i oscillations, ROS production, and NFATc1 translocation into
the nucleus in BMMs. Therefore, LrB can inhibit osteoclast differentiation and function by suppressing
[Ca2+]i oscillations, ROS, and NFATc1 activities. LrB also exerts a protective effect on OVX-induced
osteoporosis in a mouse model [93].
4.3.12. Calreticulin
Calreticulin (CRT) is a Ca2+-binding protein that regulates intracellular Ca2+ homeostasis by
modulating cytoplasmic and ER Ca2+ levels [129–131]. Fischer et al. [94] found that exogenous CRT
has an anti-osteoclastogenic effect in vitro and in vivo. Recombinant CRT Inhibits RANKL-induced
[Ca2+]i oscillations, but not ionomycin-induced Ca2+ influx in BMMs. Recombinant CRT also blocks
expression of NFATc1 and c-Fos, but not CREB and NF-κB in RAW264.7 cells.
4.3.13. 6-Shogaol
Shogaols are significant biomarkers used for the quality control of ginger-containing products
and responsible for the pungent flavor in dried ginger. Among them, 6-shogaol is the most common
type [132]. The 6-shogaol inhibits RANKL-induced [Ca2+]i oscillations, ROS production, and NFATc1
activities in BMMs. Furthermore, 6-shogaol attenuates osteoclastogenesis and alveolar bone resorption
in a ligature-induced periodontitis model in vivo [95].
4.4. Increasing [Ca2+]i Oscillations
Amyloid Beta Peptide
Amyloid beta peptide (Aβ) is the principal component of the accumulations of β-amyloid
found in the brains of Alzheimer’s patients [133]. Various studies have addressed the role of Aβ
in osteoclasts [134–136]. Specifically, a recent study showed that Aβ enhances RANKL-induced
osteoclast activation and functions through nuclear factor-κB inhibitor α (IκB-α) degradation,
extracellular-signal-regulated kinase (ERK) phosphorylation, and increased [Ca2+]i oscillations in
BMMs [96].
5. Closing Remarks and Perspectives
The crucial studies on Ca2+ signaling in osteoclastogenesis have highlighted its role in bone
biology. Considering the involvement of Ca2+ signaling in bone biology, the relatively few studies
available to date suggest the importance of TRP channels for modulating osteoclastogenesis and bone
loss. Therefore, most of the therapeutic potentials remain open. We estimate that pharmacological
targeting of this membrane channels may result in the development of therapeutics that facilitate or
inhibit Ca2+ influx.
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Abbreviations
RANKL receptor activator of nuclear factor-κB (NF-κB) ligand
M-CSF macrophage colony-stimulating factor
NFATc1 nuclear factor of activated T cells
Ca2+ calcium
TRAF6 tumor necrosis factor (TNF) receptor-associated factor 6




IP3 inositol 1, 4, 5-triphosphate
[Ca2+]i intracellular Ca2+ concentration
ER endoplasmic reticulum
SOCE store-operated Ca2+ entry
TRP transient receptor potential
SERCA Sarco/endoplasmic reticulum Ca2+-ATPase
ROS reactive oxygen species
CaM calmodulin
Homer2/3 Homer2 and Homer3
DKO double-knockout
TRPCs Transient receptor potential canonical channel
TRPVs Transient receptor potential vanilloid channel
TRPMs Transient receptor potential melastatin channel
TRPMLs Transient receptor potential mucolipin channel
TRPPs Transient receptor potential polycystin channel
TRPAs Transient receptor potential ankyrin channel
I-mfa inhibitor of MyoD family isoform a
ICRAC Ca2+ release-activated Ca2+ current




STIM1 Stromal interaction molecule 1
FSS fluid shear stress
siRNA small interfering RNA
ERα estrogen receptor α
CCN Ca2+-Calcineurin-NFATc1
OVX ovariectomized
BMMs bone marrow–derived macrophages
OAA Oleanolic acid acetate
LPS lipopolysaccharide
HAR Harpagoside
Btk Bruton’s tyrosine kinase
Syk spleen tyrosine kinase
MG Methyl gallate
TN Tatarinan N
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CaMK Ca2+/calmodulin dependent protein kinase
CREB cAMP-responsive element-binding protein
GH Glechoma hederacea
VGCCs voltage-gated Ca2+ channels
PO Portulaca oleracea
POEE Portulaca oleracea ethanol extract
MTX Methotrexate
XAT Xanthotoxin
CaMKK Calmodulin-dependent protein kinase kinase
Pyk2 Proline-rich tyrosine kinase 2
SIN Sinomenine
RA rheumatoid arthritis




TPC2 two pore segment channel 2
IP3R1 inositol 1,4,5-triphosphate receptor type 1
LrB Loureirin B
CRT Calreticulin
Aβ Amyloid beta peptide ()
IκB-α nuclear factor-κB inhibitor α
ERK extracellular-signal-regulated kinase
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